PCM
RUBY

Pathway Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Pathway Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-73,667
Closed -$1.8M – 33
2021
Q2 		$1.8M Buy
73,667
+65,105
+760% +$1.63M 0.71% 18
2021
Q1 		$227K Buy
+8,562
New +$125K 1.26% 6

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Pathway Capital Management's RUBY Position: Q3 2021 in Review

Pathway Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2021, closing a stake of 73,667 shares — an estimated $1.8M sold.

Pathway Capital Management first reported a position in RUBY in Q1 2021 and held it in 2 quarters. The position peaked at $1.8M in Q2 2021. 105 funds tracked by Wall St. Rank hold RUBY as of Q3 2021.

  • Pathway Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q3 2021 after selling out during the quarter.
  • Pathway Capital Management sold 73,667 Rubius Therapeutics, Inc shares in Q3 2021, an estimated $1.8M.
  • Pathway Capital Management first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 2 quarters.
  • Pathway Capital Management's Rubius Therapeutics, Inc position peaked at $1.8M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2021.

Based on Pathway Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.